Pharma BD Deal Intelligence
A three-year AI-RNAi collaboration, not an acquisition: Alnylam paid Inceptive $30 million upfront to apply its generative RNA foundation models to siRNA design, with milestones that could reach $2 billion. The structure bets Inceptive's AI can accelerate Alnylam's 20-year siRNA discovery engine ahead of its 2030 strategy, though the deal's actual payout depends entirely on preclinical and regulatory milestones still ahead.
Alnylam hops on AI train with up to $2B Inceptive partnership. Alnylam is gaining access to AI tools it hopes will speed the discovery of new RNA-based…
Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics. The deal gives Alnylam access to Inceptive's biology-trained AI…
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive. Alnylam partnered with Inceptive to integrate generative AI into RNAi drug discovery,…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
On June 3, 2026, Alnylam Pharmaceuticals and AI biotech Inceptive (Inceptive Nucleics) — founded by former Transformer co-author Jakob Uszkoreit — formed a three-year strategic AI collaboration to apply Inceptive's generative AI / RNA foundation models to the design and screening of small interfering RNA (siRNA) molecules for Alnylam's RNAi therapeutic platform. Inceptive receives $30 million upfront in cash and equity and is eligible for preclinical, regulatory and commercial milestones bringing the deal's total potential value to up to $2 billion. The collaboration pairs Alnylam's 20+ years of proprietary siRNA data with Inceptive's foundation models to accelerate RNAi discovery productivity in support of Alnylam's 2030 strategy.
Alnylam and AI biotech Inceptive (Inceptive Nucleics) formed a strategic collaboration to apply Inceptive's generative AI / RNA foundation models to the design and screening of siRNA molecules for Alnylam's RNAi platform. Inceptive receives $30M upfront (cash + equity) and is eligible for milestones bringing total potential value to up to $2B. The collaboration aims to accelerate Alnylam's RNAi discovery productivity. No drug asset disclosed.
Transaction between Alnylam Pharmaceuticals and Inceptive Nucleics is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alnylam Pharmaceuticals Inc. / Inceptive Nucleics, Inc. (this deal) | 2026 | $2.0B | 58 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |